Anticholinergic Drugs Companies | Market Research Future

Top Industry Leaders in the Anticholinergic Drugs Market

Anticholinergic Drugs Key Companies Latest anticholinergic drugs Companies Update

January 2023: The Phase 3 CARTITUDE-4 study comparing CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) to pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory The Independent Data Monitoring Committee advised unblinding the research since the primary endpoint was met.

December 2022: The Janssen Pharmaceutical Companies of Johnson & Johnson, a major supplier of anticholinergic medications, announced that talquetamab, for the treatment of patients with relapsed or refractory multiple myeloma, had been submitted as a biologic in a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). Talquetamab is an experimental, over-the-counter (ready to use), bispecific T-cell engager antibody that simultaneously targets CD3 on T cells and GPRC5D, a new therapeutic target that is overexpressed on myeloma cells but not on certain normal cells.

November 2022: The world's largest and most diversified healthcare products company, Johnson & Johnson, and Abiomed, a pioneer in ground-breaking heart, lung, and kidney support technologies, announced today that they have entered into a definitive agreement under which Johnson & Johnson will purchase all of Abiomed's outstanding shares through a tender offer for an upfront cash payment of $380 per share, or a total purchase price of $1.1 trillion. A non-tradeable contingent value right (CVR) will also be given to Abiomed shareholders, entitling the holder to earn up to $35 in cash per share in the event that specified commercial and clinical milestones are reached. The boards of directors of both firms unanimously authorized the deal.List of anticholinergic drugs Key companies in the market